Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension
- PMID: 20339356
- PMCID: PMC2901868
- DOI: 10.1038/ajh.2010.59
Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension
Abstract
Background: African-Americans with hypertension are susceptible to left ventricular hypertrophy (LVH). Serum osteoprotegerin level has been reported to be associated with LVH. We investigated the association of osteoprotegerin with LV mass (LVM) in 898 African-Americans with hypertension (mean age 65 years, 71% women).
Methods: Osteoprotegerin levels were measured in serum by an immunoassay and log-transformed for analyses. LVM index (LVMi; LVM/height(2.7)) was estimated using M-mode echocardiography. Linear regression analyses using generalized estimating equations were used to assess the association of osteoprotegerin with LVMi.
Results: Serum osteoprotegerin was correlated with LVMi (r = 0.21; P < 0.0001), an estimated increase in LVMi of 5.05 (95% confidence interval 2.93, 7.17) g/m(2.7) in the highest compared to the lowest osteoprotegerin quartile. This association remained statistically significant after adjustment for conventional cardiovascular risk factors (age, sex, body mass index (BMI), history of smoking, diabetes, systolic blood pressure (BP), total and high-density lipoprotein cholesterol), estimated renal function, history of myocardial infarction and stroke, lifestyle factors (physical activity score, years of education, amount of alcohol consumption), medications (aspirin, antihypertensives, statins, estrogens), and C-reactive protein (CRP) (P = 0.02). Additionally, osteoprotegerin was correlated with early/atrial (E/A) ratio (r = -0.16; P < 0.0001), LV mean wall thickness (r = 0.17; P < 0.0001) and relative wall thickness (r = 0.14; P < 0.0001) but not ejection fraction (r = 0.04; P = 0.24) or internal end-diastolic dimension (r = 0.02; P = 0.60).
Conclusion: In African-Americans with hypertension, a higher serum osteoprotegerin level is weakly but independently associated with a higher LVM.
Conflict of interest statement
Disclosure: The authors declared no conflict of interest.
Figures

Similar articles
-
Plasma C-terminal pro-endothelin-1 is associated with left ventricular mass index and aortic root diameter in African-American adults with hypertension.J Hum Hypertens. 2011 Feb;25(2):106-13. doi: 10.1038/jhh.2010.20. Epub 2010 Feb 25. J Hum Hypertens. 2011. PMID: 20182452 Free PMC article.
-
Relationship between inappropriate left ventricular hypertrophy and ejection fraction independent of absolute or indexed mass in a community sample of black African ancestry.J Hypertens. 2013 Jan;31(1):169-76. doi: 10.1097/HJH.0b013e32835a8696. J Hypertens. 2013. PMID: 23095760
-
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.Circ Cardiovasc Imaging. 2014 May;7(3):422-9. doi: 10.1161/CIRCIMAGING.113.001275. Epub 2014 Apr 10. Circ Cardiovasc Imaging. 2014. PMID: 24723582 Clinical Trial.
-
Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness.J Cardiovasc Med (Hagerstown). 2017 Dec;18(12):954-961. doi: 10.2459/JCM.0000000000000549. J Cardiovasc Med (Hagerstown). 2017. PMID: 28787318 Free PMC article.
-
Mid-regional pro-adrenomedullin is associated with pulse pressure, left ventricular mass, and albuminuria in African Americans with hypertension.Am J Hypertens. 2009 Aug;22(8):860-6. doi: 10.1038/ajh.2009.82. Epub 2009 May 7. Am J Hypertens. 2009. PMID: 19424162 Free PMC article.
Cited by
-
Role of osteoprotegerin and its gene polymorphisms in the occurrence of left ventricular hypertrophy in essential hypertensive patients.Medicine (Baltimore). 2014 Dec;93(29):e154. doi: 10.1097/MD.0000000000000154. Medicine (Baltimore). 2014. PMID: 25546658 Free PMC article.
-
Biomarkers of left ventricular hypertrophy and remodeling in blacks.Hypertension. 2011 Nov;58(5):920-5. doi: 10.1161/HYPERTENSIONAHA.111.178095. Epub 2011 Oct 10. Hypertension. 2011. PMID: 21986506 Free PMC article.
-
Osteoprotegerin as an Emerging Biomarker of Carotid Artery Stenosis? A Scoping Review with Meta-Analysis.Diagnostics (Basel). 2025 Jan 19;15(2):219. doi: 10.3390/diagnostics15020219. Diagnostics (Basel). 2025. PMID: 39857103 Free PMC article. Review.
-
Association of OPG-RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths.J Endocrinol Invest. 2019 Apr;42(4):427-434. doi: 10.1007/s40618-018-0932-y. Epub 2018 Aug 21. J Endocrinol Invest. 2019. PMID: 30132289
-
Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease.Nutrients. 2022 Aug 21;14(16):3438. doi: 10.3390/nu14163438. Nutrients. 2022. PMID: 36014945 Free PMC article. Review.
References
-
- Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319. - PubMed
-
- Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997;234:137–142. - PubMed
-
- Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631–637. - PubMed
-
- Gannagé-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006;64:652–658. - PubMed
-
- Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490–495. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous